Johnson & Johnson Raises FY26 Earnings Outlook After Strong Q2 Performance
Johnson & Johnson reported second-quarter revenues of $25.3 billion, a year-over-year increase of 6.6%, and raised its full-year earnings guidance for 2026 to between $11.60-$11.75 per share from $11.45-$11.65. Despite the positive results, J&J's stock fell slightly at market open due to MedTech revenues falling short of analyst expectations.
Tickers: $JNJ
Topics: financial outlook medtech pharmaceuticals